Inhibiting SUMOylation for MYC-driven cancer

City of Hope researchers developed an inhibitor of SUMO1 activating enzyme subunit 1 (SAE1), an untapped target that could be used to treat MYC-driven cancers.

Previous studies have shown that small ubiquitin-like modifications (SUMO) activate the transcription factor for myelocytomatosis viral oncogene homolog (MYC; c-Myc) expression and have identified genes including SAE1 involved in SUMOylation as potential druggable targets for MYC-driven cancers (see "More Druggable than MYC")...